Animace načítání

Stránka se připravuje...

Přihlásit se Registrovat se
28 428 právních předpisů

Další údaje zde

Technická podpora

Poskytujeme technickou podporu zdarma

Zavolejte nám

+420 777 717 492

Plné znění - 32020R1182

  1. Úvodní strana
  2. Právní předpisy EU
  3. Plné znění - 32020R1182

Na co čekáte? Nečekejte už ani minutu.
Získejte přístup na tento text ještě dnes. Kontaktujte nás a my Vám obratem uděláme nabídku pro Vás přímo na míru.

Chci získat výhodný přístup

XXXXXXXX XXXXXX X XXXXXXXXX XXXXXXXXX (EU) 2020/1182

xx xxx 19. xxxxxx 2020,

xxxxxx se xxx xxxxx přizpůsobení xxxxxxxxxxx a vědeckému xxxxxxx xxxx část 3 xxxxxxx XX xxxxxxxx Evropského xxxxxxxxxx x Xxxx (XX) x. 1272/2008 x xxxxxxxxxxx, xxxxxxxxxx x xxxxxx látek a xxxxx

(Xxxx x xxxxxxxx xxx XXX)

XXXXXXXX KOMISE,

s xxxxxxx xx Xxxxxxx x xxxxxxxxx Xxxxxxxx xxxx,

x xxxxxxx xx xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) x. 1272/2008 xx xxx 16. xxxxxxxx 2008 o xxxxxxxxxxx, xxxxxxxxxx x balení xxxxx x xxxxx, x xxxxx x xxxxxxx směrnic 67/548/EHS x 1999/45/ES x x xxxxx xxxxxxxx (XX) x. 1907/2006&xxxx;(1), x xxxxxxx na xx. 37 odst. 5 xxxxxxxxx nařízení,

vzhledem x xxxxx důvodům:

(1)

Tabulka 3 x xxxxx 3 xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 obsahuje seznam xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx nebezpečných látek xx xxxxxxx xxxxxxxx xxxxxxxxxxx x xxxxxxx 2 xx 5 xxxxxxx X uvedeného xxxxxxxx.

(2)

Xxxxxxxx agentuře xxx xxxxxxxx látky („agentura“) xxxx x xxxxxxx x článkem 37 xxxxxxxx (XX) x. 1272/2008 xxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx x xxxxxxxxxxx xxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx x xxxxxxxx některých xxxxxx xxxxx. Xx základě xxxxxxxxxx&xxxx;(2) x xxxxx xxxxxxx, xxxxx xxxxx Xxxxx xxx posuzování xxxxx („RAC“) xxxxxxxx, xxxxx x připomínek xxxxxxxxxxxx xxxxx, xx xxxxxx xxxxxx, aktualizovat xx xxxxxx harmonizované xxxxxxxxxxx x xxxxxxxx xxxxxxxxx xxxxx. Xxxxxxx xxxxxxxxxx výboru XXX xxxx:

—

xxxxxxxxxx xx dne 8. června 2018 xxxxxxx xxxxxxxx dusičné... %[X ≤ 70 %],

—

xxxxxxxxxx ze xxx 9. března 2018 xxxxxxx xxxxxx x xxxxxxx xxxxxxx (x xxxxxxx &xx; 3 μx,xxxxx &xx; 5 μx a poměru xxxxx ≥ 3:1),

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 ohledně xxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxx(xxxxx)xxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxxx, 6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxx-xxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxxx xxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxx (N-hydroxy-N-nitrosocyklohexylaminato-O,O’)-mědi, xxx(X-xxxxxxxxxx-xxxxxxxxx-xxxxx)-xxxx, [Xx-XXX],

—

xxxxxxxxxx xx xxx 14. xxxx 2018 ohledně dioktyltin-dilaurátu, [1] xxxxxxxx, xxxxxxx-, xxx(xxxx xxxxxxx) xxxxxxxx [2],

—

xxxxxxxxxx xx dne 30. listopadu 2018 xxxxxxx dibenzo[def,p]chrysenu, xxxxxxx[x,x]xxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx (ISO), (1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxx(2-(2-xxxxxxxxxxxxx)xxxxx)xxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 8. xxxxxx 2018 xxxxxxx paklobutrazolu (XXX), (2XX,3XX)-1-(4-xxxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx 2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxx, (2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xxx,

—

xxxxxxxxxx xx xxx 28. ledna 2019 ohledně 2-(4-xxxx-xxxxxxxxxxx)xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx XXXX-xxxxxxxxxx (XXX), X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxxx, S-ethyl 4-xxxxx-x-xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx,

—

xxxxxxxxxx xx xxx 14. září 2018 xxxxxxx 4-{[(6-chloropyridin-3-yl)methyl](2,2-difluoroethyl)amino}furan-2(5H)-onu, flupyradifuronu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxxxxxx-xxxxxxx (XXX), xxxxxx 4- [(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx ze xxx 9. března 2018 ohledně X-(+)-xxxxxx xxxxxxxx, (2X)-2-xxxxxxxxxxxxxxxx xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx 2-xxxxxxxxxxxx-xxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 xxxxxxx xxxxxxxxxx kyseliny …%,

—

xxxxxxxxxx ze xxx 14. xxxx 2018 xxxxxxx xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx, [xxxxxxxxxxx xxxxxxxx x xxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně (xxxxx-XXX-xxxxx)xxxxxxxxxxx xxxxxxxxxx, xxxxxxxxxx(xxxxxxx)xxxxxx-1-xxxxx, xxxxxxxx xxxx, [K-HDO],

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxx-xxxxxxxxxxx, X-xxxxx-X,X-xxxxxxxxxxxxxxxxx-1-xxxxxxx-xxxxx-xxxxxxx, xxxxxxxxxxx-xxxxx-xxxxxxx [XXX],

—

xxxxxxxxxx xx dne 9. března 2018 xxxxxxx (2XX)-2-[4-(4-xxxxxxxxxxx)-2(xxxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xxx, xxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxx (XXX), 1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxxx,

—

xxxxxxxxxx xx dne 14. xxxx 2018 xxxxxxx xxxxxxxxx-xxxxx, (T-4)-bis[1-(hydroxy-kappa-O)pyridin-2(1H)-thionát-kappa-S]zinku,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-xxxxx-4-(xxxxxxxxxxx)-1-[3-xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xxx, xxxxxxxxxxxxxxx (XXX),

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXXXX],

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx 2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xxx, [MBIT],

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx 3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxxx, xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 8. xxxxxx 2018 ohledně N-(hydroxymethyl)akrylamidu, xxxxxxxxxxxxxxxxxx, [XXX],

—

xxxxxxxxxx ze xxx 15. října 2018 ohledně 5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamidu, 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxxx, xxxxxxxxxx,

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxxxx (XXX), xxxxxxxxx [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamátu,

—

stanovisko xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxxxxxxxx (ISO), X-xxxxx-4,5-xxxxxxxx-2(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 ohledně xxxxxxx, xxxxxxx [olej xxxxxxxx xx studena xx xxxxx xxxxxxxx Xxxxxxxxxxx indica bez xxxxxxxx, extrahovaný superkritickým xxxxxx xxxxxxxxx],

—

xxxxxxxxxx xx xxx 8. června 2018 xxxxxxx xxxxxxxx xxxxxxx …%[C> 70 %],

—

xxxxxxxxxx x 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxxxxxxxx, [X4],

—

xxxxxxxxxx ze xxx 30. xxxxxxxxx 2018 ohledně xxxxxxxxx-xxxxxxx (XXX), O-[2-(diethylamin)-6-methylpyrimidin-4-yl]-O,O-dimethyl-fosforthioátu,

—

stanovisko ze 30. listopadu 2018 xxxxxxx fosfinu,

—

stanovisko xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx 2-xxxxxxxxxx-10-xxxxx-4,4-xxxxxxx-7-xxx-8-xxx-3,5-xxxxxx-4-xxxxxxxxxxx-xxxxxxxxx, [XXXX],

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx xxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx 2-xxxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 ohledně m-bis(2,3-epoxypropoxy)benzenu, xxxxxxxxxx-xxxxxxxxxx-xxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx-xxxxxxx (XXX), xxxxxx 2-[N-(4-methoxy-6-methyl-1,3,5-triazin-2-yl)-N-methylkarbamoylsulfamoyl]benzoátu,

—

stanovisko xx xxx 8. xxxxxx 2018 xxxxxxx azoxystrobinu (XXX), xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), (XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 30. xxxxxxxxx 2018 ohledně 2,4-xxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx xxxxxxxxxx (ISO), 2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx xxxxxxxxxxx (XXX), 2-xxxxx-2X-xxxxxxxxxx-3-xxx, [XXX],

—

xxxxxxxxxx ze xxx 14. září 2018 ohledně hymexazolu (XXX), 3-xxxxxxx-5-xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxxx hexythiazoxu (XXX), xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 9. března 2018 xxxxxxx xxxxxxxxxxx (XXX), (X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxx-xxxxx)-1,2,4-xxxxxxx-3(2X)-xxx,

—

xxxxxxxxxx ze xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx (XXX), xxxxxxx xxxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxxx, [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxxxx-xxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 14. xxxx 2018 xxxxxxx-xxxxx, ethylmethylketoximu, xxxxxxxxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx dne 8. xxxxxx 2018 xxxxxxx xxx(α,α-xxxxxxxxxxxxxx)-xxxxxxxx,

—

xxxxxxxxxx xx xxx 9. xxxxxx 2018 xxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxxxx,

—

xxxxxxxxxx xx xxx 30. listopadu 2018 xxxxxxx hexyl 2-(1-(xxxxxxxxxxxxxxxxxxxxxxxx) xxxxxxxxx)xxxxxxxx, xxxxx 2-[4-(xxxxxxxxxxx)-2-xxxxxxxxxxxxxx]xxxxxxxx.

(3)

Xxxxx xxx o xxxxx xxxxx (xxxxx XXX 7439–92–1 a xxxxxxxx xxxxx 082–013–00–1 (xxxxx x xxxxxx; [průměr xxxxxx < 1 xx];) x 082–014–00–7 (xxxxxxxx xxxxx; [xxxxxx xxxxxx ≥ 1 xx];)), XXX xx xxxx xxxxxxxxxx xx xxx 30. xxxxxxxxx 2018 xxxxxx xxxxxx xxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxx xx xxxxxxxxx x xxxxxxxxx formu. Xxxxx xxxxxxxx k xxxxx xxxxxxxxx rozpouštění xxxxxxxx xxxxx, tvárné xxxxxxxxx xxxxx, xx specifické xxxxxxx výrobě xxxxxx x xxxxxxxx k xxxxx xxxxxxxxxxxxxxx klasifikaci x xxxxxxxxxx x xxxxxxxxxx forem xxxxxx xxxx x xxxxxxxxxxxx xxxxxxxxx v xxxxxxx XX musí RAC xxxxxxx xxxxx posouzení xxxx, xxx xx xxx na xxxxxxxxx x xxxxxxxxx xxxxx xxxxx xxxxxxx xxxxxx xxxxxxxxxxxxxxx klasifikace. Xxxxx xxxx byly předloženy xxxx vědecké xxxxxxxx, x xxxxx vyplývá, xx environmentální klasifikace xxx xxxxxxxxx xxxxx, xxx ji xxxxxxxxxx xxxxxxxxxx xxxxxx XXX, xxxxxx xxx xxxxxx. Xxxxxxxxxxxxxxx klasifikace xxx xxxxxxxxx xxxxx xxxxx xxxxxx zařazena xx xxxxxxx XX xxxxxxxx (XX) č. 1272/2008, xxxxx RAC xxxxxx xxx xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxxxxxx.

(4)

Xxxxx jde x látku 2-xxxxxxxxxxxxx, xxxxxxxxxxxxx-xxxxxxxxx-xxxxx, (xxxxx XXX 111-76-2), xxx xxxxx xxxxxxxxxxxxx „xxxxxx xxxxxxxx (xxxxxxxxx)“ byly xxxxxxxxxx xxxx xxxxxxx xxxxxxxx, xx xxxxxxx xxxxxxx, xx xxxxxxxxxxx xxx xxxx xxxxx nebezpečnosti xxxxxxxxxxxx ve stanovisku xxxxxx XXX, xxx xx xxxxxxx na xxxxxxxx xxxxxxx, xxxxxx xxx xxxxxx. Tato xxxxx nebezpečnosti by xxxxx xxxxxx xxx x příloze XX xxxxxxxx (ES) č. 1272/2008 xxxxxxx, dokud XXX xxxxxx mít xxxxxxx xxxxxxxxx x xxxxx xxxxx informacím xxxxxxxxxx stanovisko; xxxxxxx xxxxxxx třídy nebezpečnosti, x xxxxxxx xxxxxxxxx xxxxxxxxxx xxxxxx RAC, xx zařazeny být xxxx.

(5)

Xxxxxxxx (XX) č. 1272/2008 by proto xxxx xxx xxxxxxxxxxxxx xxxxxxxx změněno.

(6)

Dodržování nových xxxx xxxxxxxxxxxxxxx harmonizovaných xxxxxxxxxxx xx nemělo xxx, s xxxxxxxx xxxxxxxxxxx regulatorních požadavků, xxxxxxxxxx xxxxx, xxxxxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxx na xx, xxx xxxxxxxxxxxx xxxxxxxxxx x xxxxxx xxxxx x xxxxx xxxxx xxxx xxxxxxxxxxx klasifikacím x xxxxxxx xxxxxxxxx xxxxxx. Xxxx xxxx xx xxxxxx nezbytná x tomu, xxx xxxxxxxxxx měli xxxxxxxx xxxx přijmout opatření xxxxx x xxxxxxxxx xxxxxxxx dodržování xxxxxxx xxxxxxxx xxxxxxxxx, které xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxx podle xxxxxx xxxxxxxx. Xxxx xxxxxxxxx xxxxx zahrnovat xxxxxxxxx stanovené x xx. 22 xxxx. 1 písm. x) xxxxxxxx Xxxxxxxxxx parlamentu x Xxxx (XX) x. 1907/2006 (3) nebo xxxxxxxxx xxxxxxxxx x xxxxxx 50 nařízení Xxxxxxxxxx xxxxxxxxxx x Xxxx (XX) č. 528/2012&xxxx;(4).

(7)

Xxxxxxxxxxx xx xxxx xxxx xxx umožněno, xxx xxxxx xxxx xxxxxxxxxx xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxx a xxxxxx uplatňovat dobrovolně xxxxx dnem xxxxxxxxxxxxx xxxxxx xxxxxxxx. Xx xx x xxxxxxx x xxxxxxxxx podle xx. 61 odst. 2 xxxxxxxx (XX) x. 1272/2008,

XXXXXXX XXXX XXXXXXXX:

Xxxxxx 1

Xxxxx nařízení (XX) x. 1272/2008

Tabulka 3 x xxxxx 3 přílohy VI xxxxxxxx (ES) č. 1272/2008 se xxxx x xxxxxxx x xxxxxxxx tohoto nařízení.

Xxxxxx 2

Vstup x xxxxxxxx x xxxxxxxxxxxx

Xxxx xxxxxxxx vstupuje x xxxxxxxx xxxxxxxx dnem xx xxxxxxxxx v Xxxxxxx xxxxxxxx Evropské xxxx.

Xxxxxxx se xxx xxx 1. xxxxxx 2022.

Xxxxxxxx xx druhého xxxxxxxxxxx xxxxxx xxxxxx xxxxx xxx xxxxx x xxxxx klasifikovány, xxxxxxxxxx x xxxxxx x xxxxxxx s xxxxxxxxx (XX) x. 1272/2008 xx xxxxx xxxxxx xxxxxxxx xxxxx xxxxx dnem 1. xxxxxx 2022.

Xxxx xxxxxxxx xx xxxxxxx v xxxxx xxxxxxx x xxxxx xxxxxxxxxx xx xxxxx xxxxxxxxx xxxxxxx.

X Xxxxxxx xxx 19. xxxxxx 2020.

Xx Komisi

Ursula VON XXX XXXXX

xxxxxxxxxxx

(1)&xxxx;&xxxx;xxxxXx. xxxx. X 353, 31.12.2008, x. 1.

(2)  Stanoviska jsou xxxxxxxx xx xxxx xxxxxxxxxxx xxxxxxx: xxxxx://xxxx.xxxxxx.xx/xxxxxxxx-xx-xxx-xxxxxxxxxx-xxxxx-xxxxxxx/-/xxxxxxx/xxxx/-/xxXxxxxx/-/xxxXxxxxx/-/xxx_xxxxxxxXxxx/-/xxx_xxxxxxxXx/-/xxx_xxxxxx_xxxxxx/Xxxxxxx+Xxxxxxx/xxx_xxxxxxxxxXxxx/-/xxx_xxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxxxxXxxx/-/xxx_xxxxxxxx_xxxxxxxxXx/-/xxx_xxxxxxxx_xxxxxx/-/xxx_xxxxxxxxx/-/xxx_xxxxxxxxxxXxxx/-/xxx_xxxxxxxxxxXx/-/xxx_xxxxxxxxxx_xxxxxxxxx/-/

(3)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx a Xxxx (XX) x. 1907/2006 ze xxx 18. prosince 2006

x xxxxxxxxxx, xxxxxxxxx, povolování x omezování xxxxxxxxxx xxxxx, o xxxxxxx Xxxxxxxx xxxxxxxx xxx xxxxxxxx xxxxx, x xxxxx směrnice 1999/45/XX x x xxxxxxx xxxxxxxx Rady (XXX) x. 793/93, xxxxxxxx Xxxxxx (XX) x. 1488/94, xxxxxxxx Xxxx 76/769/XXX a směrnic Xxxxxx 91/155/XXX, 93/67/XXX, 93/105/XX x 2000/21/ES (Xx. věst. X 396, 30.12.2006, s. 1).

(4)&xxxx;&xxxx;Xxxxxxxx Xxxxxxxxxx xxxxxxxxxx x Rady (XX) x. 528/2012 xx xxx 22. května 2012

x dodávání biocidních xxxxxxxxx xx trh x jejich xxxxxxxxx

(Xx. xxxx. X 167, 27.6.2012, x. 1).

XXXXXXX

X xxxxxxx XX xxxxxxxx (XX) x. 1272/2008 xx xxxxxxx 3 x xxxxx 3 xxxx xxxxx:

1)

Xxxxxxxx xx xxxx xxxxxxx:

Xxxxxxxx xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx koncent. limity, xxxxxxxxxxxxx xxxxxxx x XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx nebezpečnosti

Kódy xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxxx xxxx

Xxxx standardních xxx x nebezpečnosti

Kódy xxxxx. xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

„007-030-00-3

xxxxxxxx xxxxxxx …% [X ≤ 70 %]

231-714-2

7697-37-2.

Xx. Liq. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1 X

X272

X331

X314

XXX03

XXX06

XXX05

Xxx

X272

X331

X314

XXX071

Xx. Xxx. 3; H272: X ≥ 65 %

xxxxxxxxx: ATE = 2,65 xx/x (páry)

Skin Xxxx. 1 X; X314: X ≥ 20 %

Xxxx Xxxx. 1X; H314: 5 % ≤ C &xx; 20 %

B“

„014-048-00-5

vlákna x xxxxxxx křemíku (x průměru < 3 μx, xxxxx &xx; 5 μm x s xxxxxxx xxxxx ≥ 3:1)

206-991-8

409-21-2

308076-74-6

Xxxx. 1X

X350x

XXX08

Xxx

X350x“

„014-049-00-0

xxxxxxxxxxxxxxxxxxxx; xxxxxxxxxx(xxxxx)xxxxx

220-449-8

2768-02-7

Xxxx Xxxx. 1X

X317

XXX07

Xxx

X317“

„014-050-00-6

xxxx(2-xxxxxxxxxxxxx)xxxxxxxxxx;

6-(2-xxxxxxxxxxxxx)-6-xxxxx-2,5,7,10-xxxxxxxx-6-xxxxxxxxxxx

213-934-0

1067-53-4

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„016-098-00-3

xxxxxxxx-xxxxxxxx

210-871-0

624-92-0

Xxxx. Xxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 3

STOT XX 3

XXXX SE 1

Eye Xxxxx. 2

Skin Sens. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H225

H331

H301

H336

H370 (horní xxxxxxx cesty, vdechnutí)

H319

H317

H400

H410

GHS02

GHS06

GHS08

GHS09

Dgr

H225

H331

H301

H336

H370 (xxxxx xxxxxxx xxxxx, xxxxxxxxx)

X319

X317

X410

xxxxxxxxx: XXX = 5 xx/x (xxxx)

xxxxxx: XXX = 190 xx/xx XX

X = 1

X = 10“

„029-024-00-X

granulovaná xxx;

[xxxxx xxxxxx: xx 0,9 xx x xx 6,0 xx; xxxxx částic: od 0,494 do 0,949 xx]

231-159-6

7440-50-8

Xxxxxxx Chronic 2

H411

GHS09

H411“

„029-025-00-5

bis(N-hydroxy-N-nitrosocyklohexylaminato-O,O’)měď;

bis(N-cyklohexyl-diazenium-dioxy)-měď;

[Cu-HDO]

239-703-4

312600-89-8

15627-09-5

Flam. Xxx. 1

Xxxxx Tox. 4

XXXX RE 2

Eye Xxx. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X228

X302

X373 (xxxxx)

X318

X400

X410

XXX02

XXX07

XXX08

XXX05

XXX09

Xxx

X228

X302

X373 (xxxxx)

X318

X410

xxxxxx: XXX = 360 mg/kg XX

X = 1

X = 1“

„050-031-00-9

xxxxxxxxxx-xxxxxxxx; [1]

xxxxxxx, xxxxxxx-, bis(koko xxxxxxx) xxxxxxxx [2]

222-883-3 [1] 293-901-5 [2]

3648-18-8 [1] 91648-39-4 [2]

Xxxx. 1X

XXXX XX 1

H360D

H372 (xxxxxxxx xxxxxx)

XXX08

Xxx

X360X

X372 (xxxxxxxx xxxxxx)“

„601-092-00-0

xxxxxxx[xxx,x]xxxxxxx;

xxxxxxx[x,x]xxxxx

205-886-4

191-30-0

Xxxx. 1X

Xxxx. 2

X350

X341

XXX08

Xxx

X350

X341

Xxxx. 1X; X350: X ≥ 0,001 %“

„603-237-00-3

xxxxxxxxx (XXX);

(1XX,2XX,5XX;1XX,2XX,5XX)-2-(4-xxxxxxxxxxx)-5-xxxxxxxxx-1-(1X-1,2,4-xxxxxxx-1-xxxxxxxx)xxxxxxxxxxxxx

–

125225-28-7

115850-69-6

115937-89-8

Xxxx. 1X

Xxxxx Xxx. 4

STOT XX 2

Xxxxxxx Xxxxxxx 1

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

XXX08

XXX07

XXX09

Xxx

X360X

X302

X373 (xxx, xxxx, xxxxx)

X410

xxxxxx: XXX = 500 xx/xx TH

M = 100“

„603-238-00-9

xxx(2-(2-xxxxxxxxxxxxx)xxxxx)-xxxxx; xxxxxxxxx

205-594-7

143-24-8

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„603-239-00-4

xxxxxxxxxxxxx (XXX);

(2XX,3XX)-1-(4-xxxxxxxxxx)-4,4-xxxxxxxx-2-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-3-xx

–

76738-62-0

Xxxx. 2

Xxxxx Xxx. 4

Acute Tox. 4

Xxx Irrit. 2

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X361x

X332

X302

X319

X400

X410

XXX08

XXX07

XXX09

Xxx

X361x

X332

X302

X319

X410

xxxxxxxxx: ATE = 3,13 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 490 xx/xx XX

X = 10

X = 10“

„603-240-00-X

2,2-xxx(xxxxxxxxxx)xxxxxx-1,3-xxxx

221-967-7

3296-90-0

Xxxx. 1X

Xxxx. 1X

X350

X340

XXX08

Xxx

X350

X340“

„603-241-00-5

xxxxxxxx;

(2X)-3,7-xxxxxxxxxxxx-2,6-xxxx-1-xx

203-377-1

106-24-1

Xxxx Xxxx. 1

H317

GHS07

Wng

H317“

„605-041-00-3

2-(4-terc-butylbenzyl)propanal

201-289-8

80-54-6

Repr. 1X

X360Xx

XXX08

Xxx

X360Xx“

„607-738-00-8

XXXX-xxxxxxxxx (XXX);

X-xxxxx (4-xxxxx-2-xxxxxxxxxxxx)xxxxxxxxxxxx; X-xxxxx 4-xxxxx-x-xxxxxxxxxxxxxxxxxx

246-831-4

25319-90-8

Xxxxx Xxx. 4

XXXX XX. 2

Xxxxxxx Xxxxx 1 Aquatic Xxxxxxx 1

X302

X373 (xxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxx)

X410

xxxxxx: XXX = 450 mg/kg XX

X = 10

X = 10“

„607-740-00-9

xxxxxxxxxx-xxxxxx

248-523-5

27554-26-3

Xxxx. 1X

X360XX

XXX08

Xxx

X360XX“

„607-741-00-4

4-{[(6-xxxxxxxxxxxx-3-xx)xxxxxx](2,2-xxxxxxxxxxxx)xxxxx}xxxxx-2(5X)-xx; xxxxxxxxxxxxxx

–

951659-40-8

Xxxxx Xxx. 4

XXXX XX 2

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

H302

H373 (xxxxxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X373 (xxxxxxxxx)

X410

xxxxxx: XXX = 500 xx/xx XX

X = 10

M = 10“

„607-742-00-X

xxxxxxxxxxxxx-xxxxxx (XXX);

xxxxxx-4-[(4,5-xxxxxxx-3-xxxxxxx-4-xxxxxx-5-xxx-1X-1,2,4-xxxxxxx-1-xx)xxxxxxxxxxxxxxxxx]-5-xxxxxxxxxxxxx-3-xxxxxxxxxx

–

317815-83-1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X400

X410

XXX09

Xxx

X410

X = 1000

M = 1000“

„607-743-00-5

X-(+)-xxxxxx kyselina;

(2 X)-2-xxxxxxxxxxxxxxxx xxxxxxxx

201-196-2

79-33-4

Xxxx Xxxx. 1X

Xxx Xxx. 1

X314

X318

XXX05

Xxx

X314

XXX071“

„607-744-00-0

2-xxxxxxxxxxxxxxxxxxx

221-499-3

3121-61-7

Xxxx. Xxx. 3

Xxxx. 2

Xxxx. 1B

Acute Xxx. 3

Acute Tox. 4

Xxxx Xxxx. 1X

Xxx Xxx. 1

Skin Xxxx. 1

X226

X341

X360XX

X331

X302

X314

X318

X317

XXX02

XXX05

XXX06

XXX08

Xxx

X226

X341

X360XX

X331

X302

X314

X317

XXX071

xxxxxxxxx: XXX = 2,7 mg/l (xxxx)

xxxxxx: XXX = 404 xx/xx XX“

„607-745-00-6

xxxxxxxxxx kyselina …%

206-058-5

298-12-4

Xxx Dam. 1

Xxxx Xxxx. 1B

H318

H317

GHS05

GHS07

Dgr

H318

H317

B“

„607-746-00-1

natrium-N-(hydroxymethyl)glycinát;

[formaldehyd uvolněný x xxxxxxx-X-(xxxxxxxxxxxxx)xxxxxxxxx]

274-357-8

70161-44-3

Xxxx. 1X

Xxxx. 2

Xxxxx Xxx. 4

Xxxxx Xxx. 4

STOT SE 3

Xxxx Xxxxx. 2

Xxx Xxxxx. 2

Xxxx Sens. 1

X350

X341

X332

X302

X335

X315

X319

X317

XXX08

XXX07

Xxx

X350

X341

X332

X302

X335

X315

X319

X317

xxxxxxxxx: ATE = 3 mg/l (xxxxx xxxx xxxx)

xxxxxx: XXX = 1 100 xx/xx XX

8

9“

„611-181-00-6

(xxxxx-XXX-xxxxx)xxxxxxxxxx xxxxxxxx;

xxxxxxxxxxxxxxxxxxxxxxx-1-xxxx, xxxxxxxx xxx;

[X-XXX]

–

66603-10-9

Xxxx. Xxx. 1

Acute Xxx. 3

STOT XX 2

Xxxx Xxxxx. 2

Xxx Xxx. 1

Xxxxxxx Xxxxxxx 2

X228

X301

X373 (xxxxx)

X315

X318

X411

XXX02

XXX06

XXX08

XXX05

XXX09

Xxx

X228

X301

X373 (játra)

H315

H318

H411

orální: XXX = 136 xx/xx TH“

„612-294-00-3

mecetroniumetilsulfát;

N-ethyl-N,N-dimethylhexadekan-1-aminium-ethyl-sulfát;

mecetronium-ethyl-sulfát;

[MES]

221-106-5

3006-10-8

Skin Xxxx. 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X314

X318

X400

X410

XXX05

XXX09

Xxx

X314

X410

XXX071

X = 100

M = 1&xxxx;000 “

„613-331-00-6

(2XX)-2-[4-(4-xxxxxxxxxxx)-2-(xxxxxxxxxxxxxx)xxxxx]-1-(1X-1,2,4-xxxxxxx-1-xx)xxxxxx-2-xx;

xxxxxxxxxxxxxxxxxx

–

1417782-03-6

Xxxx Xxxx. 1

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X317

X400

X410

XXX07

XXX09

Xxx

X317

X410

X = 1

M = 1“

„613-332-00-1

xxxxxxxxxxxxxxx (XXX);

1-(4-{4-[5-(2,6-xxxxxxxxxxxx)-4,5-xxxxxxx-1,2-xxxxxx-3-xx]-1,3-xxxxxxx-2-xx}xxxxxxxxx-1-xx)-2-[5-xxxxxx-3-(xxxxxxxxxxxxxx)-1X-xxxxxxx-1-xx]xxxxxxx

–

1003318-67-9

Xxxxxxx Xxxxxxx 1

X410

XXX09

Xxx

X410

X = 1“

„613-333-00-7

xxxxxxxxx-xxxxx; (X-4)-xxx[1-(xxxxxxx-.xxxxx.X)xxxxxxx-2(1X)-xxxxxxxx-.xxxxx.X]xxxxx

236-671-3

13463-41-7

Xxxx. 1X

Xxxxx Tox. 2

Xxxxx Xxx. 3

XXXX XX 1

Xxx Xxx. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H360D

H330

H301

H372

H318

H400

H410

GHS08

GHS06

GHS05

GHS09

Dgr

H360D

H330

H301

H372

H318

H410

inhalační: XXX = 0,14 mg/l (xxxxx xxxx xxxx)

xxxxxx: XXX = 221 xx/xx XX

X = 1&xxxx;000

X = 10“

„613-334-00-2

flurochloridon (XXX);

3-xxxxx-4-(xxxxxxxxxxx)-1-[3-(xxxxxxxxxxxxxx)xxxxx]xxxxxxxxxx-2-xx

262-661-3

61213-25-0

Xxxx. 1X

Xxxxx Xxx. 4

Xxxx Sens. 1

Aquatic Xxxxx 1

Xxxxxxx Chronic 1

X360XX

X302

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X360XX

X302

X317

X410

xxxxxx: XXX = 500 xx/xx XX

X = 100

M = 100“

„613-335-00-8

4,5-xxxxxxx-2-xxxxx-2X-xxxxxxxxxx-3-xx; [DCOIT]

264-843-8

64359-81-5

Acute Tox. 2

Xxxxx Xxx. 4

Xxxx Xxxx. 1

Eye Dam. 1

Xxxx Xxxx. 1 X

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X330

X302

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X302

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,16 mg/l (xxxxx xxxx xxxx)

xxxxxx: XXX = 567 xx/xx XX

Xxxx Irrit. 2; X315: 0,025 % ≤ C &xx; 5 %

Eye Xxxxx. 2; X319: 0,025 % ≤ X &xx; 3 %

Xxxx Xxxx. 1 X; H317: X ≥ 0,0015 %

X = 100

M = 100“

„613-336-00-3

2-xxxxxx-1,2-xxxxxxxxxxxx-3(2X)-xx;

[XXXX]

–

2527-66-4

Xxxxx Tox. 4

Xxxxx Xxx. 3

Xxxx Xxxx. 1X

Xxx Xxx. 1

Xxxx Xxxx. 1 X

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 2

X312

X301

X314

X318

X317

X400

X411

XXX06

XXX05

XXX09

Xxx

X312

X301

X314

X317

X410

XXX071

xxxxxxxx: XXX = 1&xxxx;100 xx/xx XX

xxxxxx: XXX = 175 xx/xx XX

Xxxx Sens. 1 X; X317: X ≥ 0,0015 %

X = 1“

„616-228-00-4

3-(xxxxxxxxxxxxx)-1-xxxxxx-X-(3‘,4’,5’-xxxxxxxxxxxxxxx-2-xx)xxxxxxx-4-xxxxxxxxxx;

xxxxxxxxxxxx

–

907204-31-3

Xxxx.

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X362

X400

X410

XXX09

Xxx

X362

X410

X = 1

M = 1“

„616-230-00-5

N-(hydroxymethyl)akrylamid; xxxxxxxxxxxxxxxxx; [XXX]

213-103-2

924-42-5

Xxxx. 1X

Xxxx. 1X

XXXX XX 1

X350

X340

X372 (periferní xxxxxxx systém)

GHS08

Dgr

H350

H340

H372 (periferní xxxxxxx systém)“

„616-231-00-0

5-fluor-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)fenyl]-1H-pyrazol-4-karboxamid; 2’-[(XX)-1,3-xxxxxxxxxxxxx]-5-xxxxx-1,3-xxxxxxxxxxxxxxx-4-xxxxxxxxxxxx;

xxxxxxxxx

–

494793-67-8

Xxxx. 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X400

X410

XXX08

XXX09

Xxx

X351

X410

X = 1

X = 1“

„616-232-00-6

xxxxxxxxxxxx (XXX);

xxxxxxxxx [(2S)-3-methyl-1-{[1-(4-methylfenyl)ethyl]amino}-1-oxobutan-2-yl]karbamát

–

140923-17-7

Carc. 2

H351

GHS08

Wng

H351“

„616-233-00-1

silthiofam (XXX);

X-xxxxx-4,5-xxxxxxxx-2-(xxxxxxxxxxxxxx)xxxxxxx-3-xxxxxxxxxx

–

175217-20-6

XXXX XX 2

Xxxxxxx Xxxxxxx 2

X373

X411

XXX08

XXX09

Xxx

X373

X411“

„650-057-00-6

Xxxxxxx, xxxxxxx [xxxx xxxxxxxx xx xxxxxxx xx semen xxxxxxxx Xxxxxxxxxxx indica xxx xxxxxxxx, xxxxxxxxxxx xxxxxxxxxxxxxx xxxxxx uhličitým]

283-644-7

84696-25-3

Aquatic Xxxxxxx 3

H412

H412“

2)

položky odpovídající xxxxxxxxx číslům 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616–014–00–0 a 617–006–00-X xx xxxxxxxxx xxxxxx položkami:

Indexové xxxxx

Xxxxxxxx xxxxx

Xxxxx XX

Xxxxx XXX

Xxxxxxxxxxx

Xxxxxxxx

Xxxxxxxxxx xxxxxxx. limity, multiplikační xxxxxxx a XXX

Xxxxxxxx

Xxxx xxxx x xxxxxxxxx xxxxxxxxxxxxx

Xxxx xxxxxxxxxxxx xxx x xxxxxxxxxxxxx

Xxxx xxxxxxxxxxx xxxxxxx x signálních xxxx

Xxxx standardních vět x xxxxxxxxxxxxx

Xxxx xxxxx. xxxxxxxxxxxx xxx o xxxxxxxxxxxxx

„007-004-00-1

xxxxxxxx xxxxxxx …% [X &xx; 70 %]

231-714-2

7697-37-2

Xx. Liq. 2

Xxxxx Xxx. 1

Xxxx Xxxx. 1 X

X272

X330

X314

XXX03

XXX06

XXX05

Xxx

X272

X330

X314

XXX071

Xx. Liq. 2; X272: C ≥ 99 %

Xx. Xxx. 3; X272: 70 % ≤ X &xx; 99 %

X“

„014-018-00-1

xxxxxxxxxxxxxxxxxxxxxxxxxxx;

[X4]

209-136-7

556-67-2

Xxxx. 2

Aquatic Xxxxxxx 1

X361x ***

X410

XXX08

XXX09

Xxx

X361x ***

H410

M = 10“

„015-134-00-5

xxxxxxxxx-xxxxxx (XXX);

X-[2-(xxxxxxxxxxx)-6-xxxxxxxxxxxxxxx-4-xx]-X,X-xxxxxxxx-xxxxxxxxxxxxx

249-528-5

29232-93-7

Xxxxx Xxx. 4

XXXX RE 1

Xxxxxxx Acute 1

Aquatic Xxxxxxx 1

X302

X372 (nervový xxxxxx)

X400

X410

XXX07

XXX08

XXX09

Xxx

X302

X372 (xxxxxxx xxxxxx)

X410

xxxxxx: XXX = 1&xxxx;414 xx/xx XX

X = 1&xxxx;000

X = 1 000 “

„015-181-00-1

xxxxxx

232-260-8

7803-51-2

Xxxx. Gas 1

Xxxxx. Xxx

Xxxxx Tox. 1

Skin Xxxx. 1X

Xxxxxxx Xxxxx 1

X220

X330

X314

X400

XXX02

XXX04

XXX06

XXX05

XXX09

Xxx

X220

X330

X314

X400

xxxxxxxxx:

XXX = 10 xxxX (plyny)

U“

„050-021-00-4

dichlordioktylstannan

222-583-2

3542-36-7

Repr. 1X

Xxxxx Xxx. 2

STOT XX 1

Xxxxxxx Xxxxxxx 3

H360D

H330

H372 **

X412

XXX08

XXX06

Xxx

X360X

X330

X372 **

X412

Xxxx. 1B; X360 D: X ≥ 0,03 %

xxxxxxxxx: XXX = 0.098 xx/X (xxxxx xxxx xxxx)“

„050-027-00-7

2-xxxxxxxxxx 10-ethyl-4,4-dioktyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradekanoát; [XXXX]

239-622-4

15571-58-1

Xxxx. 1X

XXXX RE 1

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X360X

X372 (imunitní xxxxxx)

X400

X410

XXX08

XXX09

Xxx

X360X

X372 (xxxxxxxx xxxxxx)

X410“

„082-013-00-1

xxxxxxx xxxxxx; [xxxxxx částic &xx; 1 xx]

231-100-4

7439-92-1

Xxxx. 1 X

Xxxx.

Xxxxxxx Acute 1

Xxxxxxx Xxxxxxx 1

X360XX

X362

X400

X410

XXX08

XXX09

Xxx

X360XX X362

X410

Xxxx. 1 X; X360X: X ≥ 0,03 %

X = 1

X = 10“

„603-014-00-0

2-xxxxxxxxxxx-1-xx;

xxxxxxxxxxxxxxxxxxxxxxxxxxxx

203-905-0

111-76-2

Xxxxx Xxx. 4*

Xxxxx Xxx. 4

Xxxx Xxxxx. 2

Eye Xxxxx. 2

X332

X302

X315

X319

XXX07

Xxx

X332

X302

X315

X319

xxxxxx: XXX = 1&xxxx;200 xx/xx XX“

„603-065-00-9

x-xxx(2,3-xxxxxxxxxxxx)xxxxxx;

xxxxxxxxxxxxxxxxxxxxxxxxx

202-987-5

101-90-6

Xxxx. 1X

Xxxx. 2

Xxxxx Tox. 3

Xxxxx Xxx. 4

Skin Xxxxx. 2

Eye Irrit. 2

Xxxx Xxxx. 1

Xxxxxxx Xxxxxxx 3

X350

X341

X311

X302

X315

X319

X317

X412

XXX08

XXX06

Xxx

X350

X341

X311

X302

X315

X319

X317

X412

xxxxxxxx: XXX = 300 mg/kg XX xxxxxx: ATE = 500 xx/xx XX“

„607-177-00-9

xxxxxxxxxx-xxxxxx (XXX);

xxxxxx-2-[X-(4-xxxxxxx-6-xxxxxx-1,3,5-xxxxxxx-2-xx)-X-xxxxxxxxxxxxxxxxxxxxxxxx]xxxxxxx

401-190-1

101200-48-0

XXXX XX 2

Xxxx Sens. 1

Xxxxxxx Xxxxx 1

Xxxxxxx Chronic 1

X373

X317

X400

X410

XXX08

XXX07

XXX09

Xxx

X373

X317

X410

X = 100

X = 100“

„607-256-00-8

xxxxxxxxxxxx (XXX);

xxxxxx (X)-2-{2-[6-(2-xxxxxxxxxxx)xxxxxxxxx-4-xxxxx]xxxxx}-3-xxxxxxxxxxxxxx

–

131860-33-8

Xxxxx Tox. 3

Xxxxxxx Xxxxx 1

Aquatic Xxxxxxx 1

X331

X400

X410

XXX06

XXX09

Xxx

X331

X410

xxxxxxxxx:

XXX = 0,7 xx/x (xxxxx nebo xxxx)

X = 10

X = 10“

„607-314-00-2

xxxxxxxxxxx (XXX);

(XX)-2-xxxxxx-2,3-xxxxxxx-3,3-xxxxxxxxxxxxxxxxxx-5-xx xxxxxxxxxxxxxx

247-525-3

26225-79-6

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X400

X410

XXX09

Xxx

X410

X = 1

X = 1“

„609-041-00-4

2,4-xxxxxxxxxxxx

200-087-7

51-28-5

Xxxxx Xxx. 3 *

Acute Xxx. 3

Acute Tox. 2

XXXX RE 1

Xxxxxxx Xxxxx 1

H331

H311

H300

H372

H400

GHS06

GHS08

GHS09

Dgr

H331

H311

H300

H372

H400

dermální: XXX = 300 xx/xx XX xxxxxx: XXX = 30 mg/kg XX“

„609-064-00-X

xxxxxxxxx (XXX);

2-[4-(xxxxxxxxxxxxxx)-2-xxxxxxxxxxxx]-1,3-xxxxxxxxxxxxxx

–

104206-82-8

Xxxx. 2

XXXX XX 2

Aquatic Xxxxx 1

Xxxxxxx Xxxxxxx 1

X361x

X373 (xxx, xxxxxxx systém)

H400

H410

GHS08

GHS09

Wng

H361d

H373 (xxx, xxxxxxx xxxxxx)

X410

X = 10

M = 10“

„613-112-00-5

xxxxxxxxxx (ISO);

2-oktyl-2H-isothiazol-3-on; [XXX]

247-761-7

26530-20-1

Xxxxx Xxx. 2

Acute Xxx. 3

Xxxxx Tox. 3

Xxxx Xxxx. 1

Xxx Dam. 1

Xxxx Sens. 1 X

Xxxxxxx Xxxxx 1 Xxxxxxx Chronic 1

X330

X311

X301

X314

X318

X317

X400

X410

XXX06

XXX05

XXX09

Xxx

X330

X311

X301

X314

X317

X410

XXX071

xxxxxxxxx: XXX = 0,27 xx/x (prach xxxx xxxx)

xxxxxxxx: ATE = 311 mg/kg XX xxxxxx: XXX = 125 xx/xx XX

Xxxx Xxxx. 1 X; X317: C ≥ 0,0015 %

X = 100

X = 100“

„613-115-00-1

xxxxxxxxx (XXX);

3-xxxxxxx-5-xxxxxxxxxxxxxx

233-000-6

10004-44-1

Xxxx. 2

Xxxxx Xxx. 4

Xxx Xxx. 1

Xxxx Xxxx. 1

Xxxxxxx Chronic 2

X361x

X302

X318

X317

X411

XXX08

XXX07

XXX05

XXX09

Xxx

X361x

X302

X318

X317

X411

xxxxxx: ATE = 1&xxxx;600 xx/xx TH“

„613-125-00-6

hexythiazox (XXX);

xxxxx-5-(4-xxxxxxxxxx)-X-xxxxxxxxxx-4-xxxxxx-2-xxx-3-xxxxxxxxxxx-xxxxxxxxxx

–

78587-05-0

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

H400

H410

GHS09

Wng

H410

M = 1

X = 1“

„613-202-00-4

xxxxxxxxxx (XXX);

(X)-4,5-xxxxxxx-6-xxxxxx-4-(3-xxxxxxxxxxxxxxxxxxxxx)-1,2,4-xxxxxxx-3(2X)-xx

–

123312-89-0

Xxxx. 2

Xxxx. 2

Xxxxxxx Xxxxxxx 1

X351

X361xx

X410

XXX08

XXX09

Xxx

X351

X361xx

X410

X = 1“

„613-259-00-5

xxxxxxxxxxx (XXX);

xxxxxxx xxxx: [2,4-xxxxx-(2-xxxxxx-1-xx)xxxxxxxxxxxx-3-xx]xxxxxx(1X)-xxx-xxxxxxxxxxxxx; [2,4-dioxo-(2-propyn-1-yl)imidazolidin-3-yl]methyl(1R)-trans-chrysanthemát

428-790-6

72963-72-5

Carc. 2

Acute Xxx. 4

Acute Xxx. 4

XXXX XX 2

Xxxxxxx Xxxxx 1

Xxxxxxx Xxxxxxx 1

X351

X332

X302

X371 (xxxxxxx xxxxxx; xxxxxx, inhalační)

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H332

H302

H371 (xxxxxxx xxxxxx; orální, inhalační)

H410

inhalační: XXX = 1,4 xx/x (xxxxx xxxx xxxx)

xxxxxx: XXX = 550 xx/xx XX

X = 10

X = 10“

„616-014-00-0

xxxxx-xx-xxxx; xxxxxxxxxxxxxxxxxx, ethyl(methyl)ketonoxim

202-496-6

96-29-7

Carc. 1X

Xxxxx Xxx. 4

Xxxxx Xxx. 3

STOT SE 3

XXXX SE 1

XXXX XX 2

Xxxx Xxxxx. 2

Xxx Dam. 1

Xxxx Xxxx. 1

X350

X312

X301

X336

X370 (horní xxxxxxx xxxxx)

X373 (xxxxxx xxxx)

X315

X318

X317

XXX08

XXX06

XXX05

Xxx

X350

X312

X301

X336

X370 (xxxxx dýchací xxxxx)

X373 (krevní xxxx)

X315

X318

X317

xxxxxxxx: XXX = 1&xxxx;100 xx/xx XX orální: XXX = 100 xx/xx XX“

„617-006-00-X

xxx(α,α-xxxxxxxxxxxxxx)xxxxxxx

201-279-3

80-43-3

Xxx. Xxxxx. X

Xxxx. 1B

Skin Irrit. 2

Xxx Xxxxx. 2

Aquatic Xxxxxxx 2

H242

H360D

H315

H319

H411

GHS02

GHS08

GHS07

GHS09

Dgr

H242

H360D

H315

H319

H411“

3)

položky xxxxxxxxxxxx xxxxxxxxx xxxxxx 601-064-00-8 x 607-693-00-4 xx xxxxxxx.